EvlaBio is a life science startup dedicated to the development of first-in-class therapeutics in the cardiovascular and cardiorenal space. The lead asset is a Therapeutic Monoclonal Antibody (mAb) targeting unphysiological FGFR4/FGF23 cardiac overdrive in the setting of chronic kidney disease (CKD).
Comprehensive datasets from rodent genetic & pharmacological studies as well as from human studies have shown that FGFR4/FGF23 overdrive in the setting of CKD is an independent driving factor for LVH, a major cause of death and mortality. Blocking cardiac FGFR4/FGF23 overdrive has the strong potential to prevent cardiac remodeling in patients with CKD.
